• Generex Biotechnology Corp., of Worcester, Mass., said its Indian licensee, Shreya Life Sciences Pvt. Ltd., of Mumbai, plans to complete the Phase III study of Oral-lyn, Generex' proprietary buccal insulin spray product, in India by the end of July and begin statistical data analysis. To date, 125 patients at 14 sites have completed the Phase III study of Oral-lyn, branded in India as Recosulin.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter